A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study will assess time to discontinuation due to lack of tolerability among patients
with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those
on atypical antipsychotic standard-of-care treatment. Lack of tolerability is defined as
discontinuation due to adverse events (AEs). Patients who complete the active treatment phase
will be eligible to continue to an optional 28 weeks of treatment extension phase. This
extension phase will assess key safety and efficacy measures.